J.W. Cole Advisors Inc. Acquires 2,348 Shares of Cardinal Health, Inc. $CAH

J.W. Cole Advisors Inc. boosted its holdings in Cardinal Health, Inc. (NYSE:CAH) by 26.0% in the 3rd quarter, Holdings Channel.com reports. The firm owned 11,373 shares of the company’s stock after acquiring an additional 2,348 shares during the period. J.W. Cole Advisors Inc.’s holdings in Cardinal Health were worth $1,785,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in CAH. Strategy Asset Managers LLC acquired a new stake in Cardinal Health during the 3rd quarter valued at approximately $775,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Cardinal Health by 15.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,833 shares of the company’s stock valued at $5,938,000 after purchasing an additional 5,030 shares during the last quarter. Atle Fund Management AB increased its position in shares of Cardinal Health by 13.1% during the third quarter. Atle Fund Management AB now owns 30,297 shares of the company’s stock worth $4,755,000 after buying an additional 3,500 shares during the period. National Pension Service increased its position in shares of Cardinal Health by 7.2% during the third quarter. National Pension Service now owns 500,340 shares of the company’s stock worth $78,533,000 after buying an additional 33,673 shares during the period. Finally, Baird Financial Group Inc. raised its stake in Cardinal Health by 107.2% during the second quarter. Baird Financial Group Inc. now owns 99,393 shares of the company’s stock worth $16,698,000 after buying an additional 51,416 shares during the last quarter. Institutional investors and hedge funds own 87.17% of the company’s stock.

Cardinal Health Stock Down 0.1%

Shares of CAH opened at $226.85 on Friday. The business’s fifty day moving average is $206.92 and its 200 day moving average is $180.13. Cardinal Health, Inc. has a 12-month low of $120.72 and a 12-month high of $230.81. The stock has a market cap of $53.90 billion, a P/E ratio of 32.64, a P/E/G ratio of 1.51 and a beta of 0.64.

Cardinal Health (NYSE:CAH) last announced its quarterly earnings results on Thursday, February 5th. The company reported $2.63 EPS for the quarter, beating analysts’ consensus estimates of $2.31 by $0.32. Cardinal Health had a net margin of 0.68% and a negative return on equity of 92.50%. The business had revenue of $65.63 billion during the quarter, compared to analyst estimates of $64.88 billion. During the same quarter in the previous year, the business posted $1.93 EPS. Cardinal Health’s quarterly revenue was up 18.8% on a year-over-year basis. On average, analysts expect that Cardinal Health, Inc. will post 7.95 EPS for the current year.

Cardinal Health News Summary

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Q2 results and raised outlook — Cardinal reported Q2 FY2026 revenue up ~19% to $65.6B and non‑GAAP EPS of $2.63 (beat), and raised fiscal‑year non‑GAAP EPS guidance to $10.15–$10.35; management cited strong specialty medicine demand and improved segment performance. PR Newswire
• Positive Sentiment: Analyst upgrade and price‑target lift — Leerink Partners raised its price target from $240 to $268 and kept an outperform rating, signaling more upside from current levels. MarketScreener
• Positive Sentiment: Street commentary and momentum coverage — Multiple outlets (Barron’s, Reuters, Zacks, TipRanks, 24/7 Wall St.) highlight the beat, raised guidance and accelerating specialty drug volumes, which has driven momentum interest in the stock. Examples: Reuters coverage on the outlook and Barron’s note on guidance lifts. Reuters
• Neutral Sentiment: Earnings call & transcripts available — Management commentary and slides from the Q2 call confirm the drivers behind the beat (specialty medicine, margin expansion, buybacks); these provide detail but no new surprises beyond the release. MSN Transcript
• Neutral Sentiment: Momentum stock analysis — Zacks highlights style‑score based momentum attributes, which can attract technical and quant funds but also increase volatility. Zacks
• Negative Sentiment: Valuation and historical ROE signal — After the rally the stock trades at an elevated P/E (~34x) and company data show a negative trailing return on equity metric, which could concern value‑focused investors and limit upside absent continued execution. Background valuation metrics

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CAH. Mizuho increased their price target on Cardinal Health from $222.00 to $235.00 and gave the stock an “outperform” rating in a report on Friday. Wells Fargo & Company raised their target price on Cardinal Health from $221.00 to $237.00 and gave the stock an “overweight” rating in a research note on Thursday, January 15th. Jefferies Financial Group boosted their price target on Cardinal Health from $220.00 to $270.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. UBS Group set a $260.00 price target on Cardinal Health and gave the stock a “buy” rating in a report on Friday. Finally, Barclays initiated coverage on shares of Cardinal Health in a research note on Monday, December 8th. They issued an “overweight” rating and a $243.00 price objective for the company. Fifteen investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Cardinal Health currently has an average rating of “Moderate Buy” and an average target price of $241.27.

Cardinal Health Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.